Explainable Time-To Predictions in Multiple Sclerosis
| dc.contributor.author | D'hondt, Robbe | |
| dc.contributor.author | Dedja, Klest | |
| dc.contributor.author | Aerts, Sofie | |
| dc.contributor.author | Van Wijmeersch, Bart | |
| dc.contributor.author | Kalincik, Tomas | |
| dc.contributor.author | Reddel, Stephen | |
| dc.contributor.author | MSBase Study Grp, MSBase Study | |
| dc.date.accessioned | 2025-04-25T19:49:43Z | |
| dc.date.available | 2025-04-25T19:49:43Z | |
| dc.date.issued | 2025 | |
| dc.description | Roos, Izanne/0000-0003-0371-3666; Van Wijmeersch, Bart/0000-0003-0528-1545; Kalincik, Tomas/0000-0003-3778-1376; Kermode, Allan/0000-0002-4476-4016; D'Hondt, Robbe/0000-0001-7843-2178; Reddel, Stephen/0000-0002-0169-3350; Mrabet, Saloua/0000-0003-2718-1828; Lugaresi, Alessandra/0000-0003-2902-5589 | en_US |
| dc.description.abstract | Background: Prognostic machine learning research in multiple sclerosis has been mainly focusing on black-box models predicting whether a patients' disability will progress in a fixed number of years. However, as this is a binary yes/no question, it cannot take individual disease severity into account. Therefore, in this work we propose to model the time to disease progression instead. Additionally, we use explainable machine learning techniques to make the model outputs more interpretable. Methods: A preprocessed subset of 29,201 patients of the international data registry MSBase was used. Disability was assessed in terms of the Expanded Disability Status Scale (EDSS). We predict the time to significant and confirmed disability progression using random survival forests, a machine learning model for survival analysis. Performance is evaluated on a time-dependent area under the receiver operating characteristic and the precision-recall curves. Importantly, predictions are then explained using SHAP and Bellatrex, two explainability toolboxes, and lead to both global (population-wide) as well as local (patient visit-specific) insights. Results: On the task of predicting progression in 2 years, the random survival forest achieves state-of-the-art performance, comparable to previous work employing a random forest. However, here the random survival forest has the added advantage of being able to predict progression over a longer time horizon, with AUROC > 60% for the first 10 years after baseline. Explainability techniques further validated the model by extracting clinically valid insights from the predictions made by the model. For example, a clear decline in the per-visit probability of progression is observed in more recent years since 2012, likely reflecting globally increasing use of more effective MS therapies. Conclusion: The binary classification models found in the literature can be extended to a time-to-event setting without loss of performance, thus allowing a more comprehensive prediction of patient prognosis. Furthermore, explainability techniques proved to be key to reach a better understanding of the model and increase validation of its behaviour. | en_US |
| dc.description.sponsorship | Research Foundation Flan-ders, Belgium [1S38023N]; Flemish government AI Research Program (FAIR) , Belgium | en_US |
| dc.description.sponsorship | Funding: This work was supported by Research Foundation Flan-ders, Belgium [grant number 1S38023N] and the Flemish government AI Research Program (FAIR) , Belgium. | en_US |
| dc.identifier.doi | 10.1016/j.cmpb.2025.108624 | |
| dc.identifier.issn | 0169-2607 | |
| dc.identifier.issn | 1872-7565 | |
| dc.identifier.scopus | 2-s2.0-85217750289 | |
| dc.identifier.uri | https://doi.org/10.1016/j.cmpb.2025.108624 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/6050 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier Ireland Ltd | en_US |
| dc.relation.ispartof | Computer Methods and Programs in Biomedicine | |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Explainable Artificial Intelligence | en_US |
| dc.subject | Survival Analysis | en_US |
| dc.subject | Multiple Sclerosis | en_US |
| dc.subject | Disability Progression | en_US |
| dc.subject | Longitudinal Data | en_US |
| dc.title | Explainable Time-To Predictions in Multiple Sclerosis | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Roos, Izanne/0000-0003-0371-3666 | |
| gdc.author.id | Van Wijmeersch, Bart/0000-0003-0528-1545 | |
| gdc.author.id | Kalincik, Tomas/0000-0003-3778-1376 | |
| gdc.author.id | Kermode, Allan/0000-0002-4476-4016 | |
| gdc.author.id | D'Hondt, Robbe/0000-0001-7843-2178 | |
| gdc.author.id | Reddel, Stephen/0000-0002-0169-3350 | |
| gdc.author.id | Lugaresi, Alessandra/0000-0003-2902-5589 | |
| gdc.author.scopusid | 58455057100 | |
| gdc.author.scopusid | 57486048000 | |
| gdc.author.scopusid | 58249888700 | |
| gdc.author.scopusid | 16314591800 | |
| gdc.author.scopusid | 8365701900 | |
| gdc.author.scopusid | 6603492432 | |
| gdc.author.scopusid | 36028311100 | |
| gdc.author.wosid | Patti, Francesco/C-3300-2011 | |
| gdc.author.wosid | Ramanathan, Sudarshini/D-4303-2013 | |
| gdc.author.wosid | Sá, Maria/Aad-4527-2021 | |
| gdc.author.wosid | Csepany, Tunde/M-1080-2019 | |
| gdc.author.wosid | Tomassini, Valentina/Hge-0655-2022 | |
| gdc.author.wosid | Laureys, Guy/Aah-6369-2019 | |
| gdc.author.wosid | Lugaresi, Alessandra/C-7743-2012 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | metadata only access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | true | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | [D'hondt, Robbe; Dedja, Klest; Vens, Celine] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Kortrijk, Belgium; [D'hondt, Robbe; Dedja, Klest; Vens, Celine] Katholieke Univ Leuven, Imec Res Grp, Itec, Kortrijk, Belgium; [Aerts, Sofie; Van Wijmeersch, Bart; Peeters, Liesbet] Hasselt Univ, Univ MS Ctr UMSC, Hasselt Pelt, Belgium; [Aerts, Sofie; Van Wijmeersch, Bart; Peeters, Liesbet] Hasselt Univ, Biomed Res Inst BIOMED, Dept Immunol, Diepenbeek, Belgium; [Aerts, Sofie; Van Wijmeersch, Bart] Noorderhart Rehabil & MS Ctr, Pelt, Belgium; [Aerts, Sofie; Van Wijmeersch, Bart] UHasselt, Fac Rehabil Sci, Rehabil Res Ctr REVAL, Diepenbeek, Belgium; [Kalincik, Tomas; Roos, Izanne] Royal Melbourne Hosp, Dept Neurol, Neuroimmunol Ctr, Melbourne, Australia; [Kalincik, Tomas; Roos, Izanne] Univ Melbourne, Dept Med, CORE, Melbourne, Australia; [Reddel, Stephen; Hardy, Todd A.] Concord Repatriat Gen Hosp, Dept Neurol, Sydney, Australia; [Havrdova, Eva Kubala] Charles Univ Prague, Gen Univ Hosp Prague, Fac Med 1, Prague, Czech Republic; [Havrdova, Eva Kubala] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic; [Havrdova, Eva Kubala] Gen Univ Hosp, Prague, Czech Republic; [Lugaresi, Alessandra] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy; [Lugaresi, Alessandra] IRCCS Ist Sci Neurol Bologna, Bologna, Italy; [Weinstock-Guttman, Bianca] Jacobs MS Ctr Treatment & Res, Buffalo, NY 07601 USA; [Mrabet, Saloua] Razi Univ Hosp, Clin Invest Ctr Neurosci & Mental Hlth, Dept Neurol, LR 18SP03, Tunis, Tunisia; [Mrabet, Saloua] Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia; [Lalive, Patrice] Geneva Univ Hosp, Fac Med, Dept Neurosci, Div Neurol, Geneva, Switzerland; [Lalive, Patrice] Fac Med, Geneva, Switzerland; [Kermode, Allan G.; Carroll, William M.] Univ Western Australia, Perron Inst Neurol & Translat Sci, Perth, WA, Australia; [Kermode, Allan G.] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Perth, WA, Australia; [Ozakbas, Serkan] Izmir Univ Econ, Med Point Hosp, Izmir, Turkiye; [Ozakbas, Serkan] Multiple Sclerosis Res Assoc, Izmir, Turkiye; [Patti, Francesco] GF Ingrassia, Dept Med & Surg Sci & Adv Technol, Catania, Italy; [Patti, Francesco] Univ Catania, UOS Multiple Sclerosis, AOU Policlin G Rodolico San Marco, Catania, Italy; [Prat, Alexandre] Ctr Hospitalier Univ Montreal CHUM, Montreal, PQ, Canada; [Prat, Alexandre] Univ Montreal, Montreal, PQ, Canada; [Tomassini, Valentina] Univ G dAnnunzio, Inst Adv Biomed Technol ITAB, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Tomassini, Valentina] SS Annunziata Univ Hosp, Clin Neurol, MS Ctr, Chieti, Italy; [Alroughani, Raed] Amiri Hosp, Dept Med, Div Neurol, Sharq, Kuwait; [Gerlach, Oliver] Zuyderland Med Ctr, Acad MS Ctr Zuyd, Dept Neurol, Sittard Geleen, Netherlands; [Gerlach, Oliver] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Neurol, Med Ctr, NL-6131 BK Maastricht, Netherlands; [Khoury, Samia J.] Amer Univ Beirut, Med Ctr, Nehme & Therese Tohme Multiple Sclerosis Ctr, Beirut, Lebanon; [van Pesch, Vincent] Clin Univ St Luc, Dept Neurol, Brussels, Belgium; [van Pesch, Vincent] Catholic Univ Louvain, Louvain, Belgium; [Sa, Maria Jose] Ctr Hosp Univ Sao Joao, Dept Neurol, Porto, Portugal; [Sa, Maria Jose] Inst Invest Inovacao & Desenvolvimento Fernando Pe, FP I3ID, Porto, Portugal; [Sa, Maria Jose] FCS UFP, Fac Ciencias Saude, Porto, Portugal; [Sa, Maria Jose] Univ Fernando Pessoa UFP, Rede Invest Saude RISE, Rede Invest Saude, P-4249004 Porto, Portugal; [Prevost, Julie] CSSS St Jerome, St Jerome, PQ, Canada; [Spitaleri, Daniele] Azienda Osped Rilievo Nazl San Giuseppe Moscati Av, Avellino, Italy; Royal Brisbane & Womens Hosp, Dept Neurol, Brisbane, Australia; Univ Queensland, Brisbane, Australia; [Solaro, Claudio] Galliera Hosp, Dept Neurol, Genoa, Italy; [Solaro, Claudio] ML Novarese Hosp Moncrivello, Dept Rehabil, Moncrivello, Italy; [van der Walt, Anneke; Al-Asmi, Helmut Butzkueven Abdullah] Alfred Hosp, Dept Neurol, Melbourne, Australia; [van der Walt, Anneke; Al-Asmi, Helmut Butzkueven Abdullah] Monash Univ, Sch Translat Med, Dept Neurosci, Melbourne, Vic, Australia; [Laureys, Guy] Univ Hosp Ghent, Dept Neurol, B-9000 Ghent, Belgium; [Sanchez-Menoyo, Jose Luis] Hosp Univ Galdakao Usansolo, Osakidetza Basque Hlth Serv, Microbiol Dept, Galdakao, Spain; [Sanchez-Menoyo, Jose Luis] Biocruces Bizkaia Hlth Res Inst, Bizkaia, Spain; [de Gans, Koen] Groene Hart Ziekenhuis, Gouda, Netherlands; [Al-Asmi, Abdullah] Sultan Qaboos Univ, Al Khoud, Oman; [Al-Asmi, Abdullah] Coll Med & Hlth Sci, Muscat, Oman; [Al-Asmi, Abdullah] Sultan Qaboos Univ Hosp, Muscat, Oman; [Deri, Norma] Hosp Gen Agudos Juan A Fernandez Capital Fed, Unidad Neurol, Buenos Aires, Capital Federal, Argentina; [Csepany, Tunde] Univ Debrecen, Fac Med, Dept Neurol, Debrecen, Hungary; [Al-Harbi, Talal] King Fahad Specialist Hosp Dammam, Neurol Dept, Dammam, Saudi Arabia; [Carroll, William M.] Sir Charles Gairdner Hosp, Perth, Australia; [Rozsa, Csilla] Jahn Ferenc Teaching Hosp, Budapest, Hungary; [Singhal, Bhim] Bombay Hosp & Med Res Ctr, Inst Med Sci, Mumbai, India; [Ramanathan, Sudarshini] Univ Sydney, Fac Med & Hlth, Kids Neurosci Ctr, Translat Neuroimmunol Grp, Sydney, Australia; [Ramanathan, Sudarshini] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Sydney, Australia; [Ramanathan, Sudarshini] Concord Hosp, Concord Clin Sch, Dept Neurol, Sydney, Australia; [Peeters, Liesbet] Hasselt Univ, Data Sci Inst DSI, I Biostat, Diepenbeek, Belgium | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.volume | 263 | en_US |
| gdc.description.woscitationindex | Science Citation Index Expanded | |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W4407204723 | |
| gdc.identifier.pmid | 39965473 | |
| gdc.identifier.wos | WOS:001434985500001 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 3.0 | |
| gdc.oaire.influence | 3.0017775E-9 | |
| gdc.oaire.isgreen | false | |
| gdc.oaire.keywords | Multiple sclerosis | |
| gdc.oaire.keywords | Disability progression; Explainable artificial intelligence; Longitudinal data; Multiple sclerosis; Survival analysis | |
| gdc.oaire.keywords | Longitudinal data | |
| gdc.oaire.keywords | Disability progression | |
| gdc.oaire.keywords | Explainable artificial intelligence | |
| gdc.oaire.keywords | Survival analysis | |
| gdc.oaire.keywords | Male | |
| gdc.oaire.keywords | Multiple Sclerosis | |
| gdc.oaire.keywords | Time Factors | |
| gdc.oaire.keywords | Prognosis | |
| gdc.oaire.keywords | Machine Learning | |
| gdc.oaire.keywords | ROC Curve | |
| gdc.oaire.keywords | Disease Progression | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Female | |
| gdc.oaire.popularity | 5.1740168E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 6.2691 | |
| gdc.openalex.normalizedpercentile | 0.96 | |
| gdc.openalex.toppercent | TOP 10% | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.crossrefcites | 1 | |
| gdc.plumx.mendeley | 6 | |
| gdc.plumx.scopuscites | 2 | |
| gdc.scopus.citedcount | 2 | |
| gdc.wos.citedcount | 1 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 |
